Logo Image
|Articles|May 22, 2014

Pharm Exec's Brands of Yesteryear: Where Are They Now?

Author(s)Ben Comer

Pharm Exec’s Brand of the Year selections from the last few years are still alive and kicking, although some have aged more gracefully than others.

Pharm Exec’s Brand of the Year selections from the last few years are still alive and kicking, although some have aged more gracefully than others.

The US drug pricing wars may be coming, but these products already made their mint. We checked back in with them to see how things are going, and to look for indicators about their future prospects. Click here for more.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more